Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Hallux

Hallux
2012 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$1.25M LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of a new dosage form intended to focus on treatment of onychomycosis and other nail disorders. The company's new dosage form offers a terbinafine drug that utilizes patented subungual administration and drug delivery to treat onychomycosis and other nail disorders, enabling patients to get quick recovery from nail disorders.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Other Healthcare Services
Primary Office
  • 23052 Alcalde Drive
  • Suite A
  • Laguna Hills, CA 92653
  • United States

+1 (949) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Hallux’s full profile, request a free trial.

Hallux Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 15-Nov-2018 $1.25M 00.000 Completed Startup
1. Early Stage VC (Series A) 10-Dec-2015 00.00 00.00 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Hallux Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Hallux Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Deerfield Management Venture Capital Minority 000 0000 000000 0

Hallux Executive Team (4)

Name Title Board
Seat
Contact
Info
Mark Taylor Ph.D Co-Founder, President, Board Member & Chief Executive Officer
Jay Birnbaum Ph.D Co-Founder, Director & Chief Scientific Officer
Robert Orr Board Member & Head of Drug Product and CMC

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

Hallux Board Members (6)

Name Representing Role Since Contact
Info
Bryan Sendrowski Hallux Board Member 000 0000
Mark Taylor Ph.D Hallux Co-Founder, President, Board Member & Chief Executive Officer 000 0000
Peter Steelman Hallux Board Member 000 0000
Robert Orr Hallux Board Member & Head of Drug Product and CMC 000 0000
William Forbes Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »